اوفلوكساسين تيڤع ٢٠٠ ملغ إسرائيل - العربية - Ministry of Health

اوفلوكساسين تيڤع ٢٠٠ ملغ

abic ltd. - ofloxacin 200 mg - tablets - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as:- acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - chronic and recurrent infections of the ear, nose, and throat. ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - infections of soft tissues and skin. - infections of the bones and joints. - abdominal infections including infections in the pelvis minor and bacterial enteritis. - infections of the kidney, urinary tract, and genital organs, gonorrhoea.prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).

امبرادكس٢٠ إسرائيل - العربية - Ministry of Health

امبرادكس٢٠

dexcel ltd - omeprazole 20 mg - caplets - omeprazole - acute duodenal ulcer. acute gastric ulcer. reflux esophagitis: treatment , long - term management. maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. zollinger-ellison syndrome. treatment and prevention of nsaid-associated duodenal and gastric ulcers or erosions in high risk patients. treatment of severe reflux oesophagitis in children overthe age of 6 year. helicobacter pylori - associated peptic ulcer disease in combination with antibiotics.

راﻣيپريل تيڤع ٥ ملغ إسرائيل - العربية - Ministry of Health

راﻣيپريل تيڤع ٥ ملغ

teva pharmaceutical indust.ltd - ramipril 5 mg - tablets - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.